AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05868876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion
Description: AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
Study NCT05808348 — intervention group
Intervention type: OTHER
Intervention: Scales and questionnaires
Description: We will ask participants about their age, gender, height, weight, education level, medical history, number of falls in the last 1 year, status and length of COVID-19-related hospitalizations, and whether they have gotten the COVID-19 vaccine. The participants will be interviewed in person as part of the evaluation process.~The Modified Baecke Physical Activity Questionnaire, the Fall Efficacy Scale-International, and the Numerical Pain Rating Scale will be used to assess the participants' levels of pain, fear of falling, and physical activity, respectively.
Study NCT05545059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: In valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg and valsartan 160mg. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
Study NCT05711394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet
Study NCT05711394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-Matching Atogepant
Description: Oral Tablet
Study NCT06020274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program
Description: The iCF-PWR program is a self-guided mental health prevention program designed for families with CF. Upon logging on to the iCF-PWR, the viewer will see two paths (i.e., child with CF or sibling) and will be encouraged by program narrator to choose the appropriate path. Each pathway (i.e., child with CF or sibling) is comprised of five text/voice-delivered, animated, interactive modules: (1) CF education, (2) CF health, (3) emotions and CF, (4) cognitive behaviour model of emotions, and (5) coping strategies. Each module takes 15-20 minutes to complete.
Study NCT05304182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EYESTAR 900
Description: The EYESTAR 900 is a device developed by Haag-Streit which utilises 3D OCT for quantitative measurements of the geometry of the entire eye, including ocular biometry and corneal topography. It is the most recent in a series of successful biometry devices by Haag-Streit (HS Pachymeter, Lenstar LS 900, LS 900 T-cone and LS 900 APS) and also allows for advanced corneal tomography examinations.
Study NCT05304182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYESTAR 900
Description: The EYESTAR 900 is a device developed by Haag-Streit which utilises 3D OCT for quantitative measurements of the geometry of the entire eye, including ocular biometry and corneal topography. It is the most recent in a series of successful biometry devices by Haag-Streit (HS Pachymeter, Lenstar LS 900, LS 900 T-cone and LS 900 APS) and also allows for advanced corneal tomography examinations.
Study NCT05304182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LENSTAR LS 900
Description: The LENSTAR LS 900 is a non-contact device for measurement of biometrical parameters of the eye, aimed to assist the calculation of intraocular lenses (IOLs) prior to intraocular lens implantation. The most common application is in preparation of cataract surgery.~This device uses OLCR (optical low-coherence reflectometry), an interferometric method to measure intraocular axial distances. Furthermore, it uses digital photography of the anterior section of the eye to measure pupil size and location, as well as the white-to-white distance of the eye. The same photographic unit, in conjunction with a specific illumination pattern, is used to measure the corneal curvature - this measurement is known as 'keratometry', or, more specifically, 'automated keratometry'.
Study NCT05304182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LENSTAR LS 900
Description: The LENSTAR LS 900 is a non-contact device for measurement of biometrical parameters of the eye, aimed to assist the calculation of intraocular lenses (IOLs) prior to intraocular lens implantation. The most common application is in preparation of cataract surgery.~This device uses OLCR (optical low-coherence reflectometry), an interferometric method to measure intraocular axial distances. Furthermore, it uses digital photography of the anterior section of the eye to measure pupil size and location, as well as the white-to-white distance of the eye. The same photographic unit, in conjunction with a specific illumination pattern, is used to measure the corneal curvature - this measurement is known as 'keratometry', or, more specifically, 'automated keratometry'.
Study NCT05138926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Manipulation
Description: high speed, low amplitude cervical manipulation
Study NCT05138926 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Cervical Manipulation
Description: Cervical mobilization without performing spinal manipulation
Study NCT05106387 — intervention group
Intervention type: OTHER
Intervention: Noninterventional
Description: No investigational treatment will be given in this noninterventional extension study
Study NCT04534543 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: MRI/Spectroscopy
Description: Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
Study NCT04729621 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TVB-009
Description: TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
Study NCT04729621 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
Study NCT04729621 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prolia®
Description: Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
Study NCT06045780 — intervention group
Intervention type: OTHER
Intervention: nothing
Description: disease
Study NCT05212922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001 + Toripalimab
Description: YH001 + Toripalimab
Study NCT06419738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral treatment (CBT)
Description: Cognitive behavioral treatment includes education about the disorder, proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients are also consulted on changing habits, adjusting behavior, exercising. Patients are instructed to adjust their behavior: quit harmful habits to limit pain in daily functional activities, maintain scientific sleep, maintain good head, neck and shoulder activities, soft diet and avoid hard foods, do exercises twice a day: open mouth wide combined with cool compresses and warm compresses.
Study NCT06419738 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level laser therapy combined with CBT (LLLT+CBT)
Description: LLLT may facilitate the release of endogenous opioids, tissue repairment and cellular respiration, increase vasodilatation and pain threshold, and decrease inflammation. Diode low-energy laser machine (Sirolaser blue, Dentsply) are set the default mode according to the correct parameters before use: wavelength 660nm, energy level 2.5 J/cm2, power source 100mW. The projection head is placed perpendicular to the muscle being projected. The laser light is shined on the pain point at the beginning of the treatment, then it will shine on muscle points in turn: temporal muscle (anterior, middle, posterior), masseter muscle (upper, middle, lower), 5 points around the temporomandibular joint area (superior, anterior, lateral, posterior, posterior subcondylar). Each masticatory muscle area is treated for 20 seconds, 3 sessions /week (different days), 10 sessions total. In addition, patients are still instructed CBT as group 1.
Study NCT06419738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal Splint combined with CBT (OS+CBT)
Description: Maxillary occlusal splints are made of hard acrylic after taking impressions of the upper dental arches, recording of centric relation (Okeson). Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night at least 8 hours/day for a period of 8 weeks.In addition, patients are still instructed CBT as group 1.
Study NCT02255903 — intervention group
Intervention type: OTHER
Intervention: ultrasound and Doppler examination
Description: ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion
Study NCT05182866 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ASP-1929 Photoimmunotherapy
Description: ASP-1929 640 mg/m\^2 IV infusion followed approximately 24 hours later by photoimmunotherapy
Study NCT05472753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Treatment, DCOOP Product, Hydroxytyrosol extract
Description: Intervention group will receive a nutritional formula from DCOOP (Spain).
Study NCT05472753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Treatment,Indukern product, Curcumin and selenium extract
Description: Intervention group will receive a nutritional formula from Indukern (Spain).
Study NCT05472753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Treatment
Description: Control group will receive a placebo (product loading substance)
Study NCT06319378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: psilocybin 25 mg sod
Description: psilocybin 25 mg sod
Study NCT06319378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: psilocybin 1 mg sod
Description: active placebo
Study NCT05708170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Ferinject Therapy Group: each patient's Iron need for repletion by the Ferinject will be determined using product SPC dosing based on patient's body weight and Hb level. Accordingly, the appropriate dose of Ferinject will be administered while ensuring that a single administration will not exceed:~* 15 mg iron/kg body weight (for administration by intravenous injection) or 20 mg iron/kg body weight (for administration by intravenous infusion)~* 1,000 mg of iron (20 mL Ferinject) The cumulative dose of Ferinject per week will not exceed 1,000 mg of iron (20 mL Ferinject).
Study NCT05708170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate 200 MG
Description: Active Control Group (standard care excl. IV Iron): Oral Ferrous sulphate 200 mg three times daily.
Study NCT05795348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Personalised Musculoskeletal Modeling
Description: Magnetic resonance images, electromyography and dynamometry data will be used to develop and inform personalised musculoskeletal models
Study NCT04841538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES101
Description: The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
Study NCT05881551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eEgg
Description: In the eEgg-Arm, patients are given the eEgg immediately before the intervention to familiarize themselves with this method. Here, the patient is asked to press the device with maximum force for five seconds, which would correspond to an NRS value of 10, and to press the eEgg only with half force, which corresponds to an NRS value of 5. Following the instruction, the current pain score present is recorded and documented using the NRS and the eEgg. The same procedure takes place at the end of the 24h observation interval when the eEgg is returned. Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.
Study NCT05881551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NRS
Description: Patients record their pain on the numeric rating scale (NRS) within the 24-hour interval. An interval from 0 to 10 is given (0 = no pain, 10 = most pain imaginable).
Study NCT06640296 — intervention group
Intervention type: DRUG
Intervention: Liposomal Amphotericin B (LAmB)
Description: collect data on tolerability and effectiveness of liposomal amphotericin B prophylaxis
Study NCT06447103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06447103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06447103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, PET/CT, and CT of the brain
Study NCT06447103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI of the brain
Study NCT06447103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06447103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06447103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium Zr 89 Girentuximab
Description: Given IV
Study NCT05905146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized pharmaceutical plan
Description: multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview
Study NCT05607472 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: blood samples for bio collection
Study NCT05607472 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnary of health estate during 18 month
Description: clinical exam Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation) during 18 months
Study NCT06563934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral enterobacterium capsules
Description: Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
Study NCT06563934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + PD-1 monoclonal antibody
Description: Lenvatinib 8mg (≤60 kg body weight) or 12 mg (> 60 kg body weight) orally once a day.~PD-1 monoclonal antibody 200mg i.v. once every 3 weeks.
Study NCT06563934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenvatinib + PD-1 monoclonal antibody
Description: Lenvatinib 8mg (≤60 kg body weight) or 12 mg (> 60 kg body weight) orally once a day.~PD-1 monoclonal antibody 200mg i.v. once every 3 weeks.
Study NCT06563934 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral enterobacterium capsules placebo
Description: Enterobacterium capsules placebo (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
Study NCT05500534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser lithotripsy with stone recognition
Description: Application of Revolix HTL+ which features automatic real-time stone recognition
Study NCT05500534 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laser lithortripsy
Description: Standard laser lithotripsy
Study NCT04993196 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: T1rho imaging
Description: Magnetic Resonance Imaging using T1rho
Study NCT06642064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: • Intervention group:~Participants were invited to participate in a 20-minute interactive learning course (PPT lecture) and a 25-minute physical activity.The intervention lasted for 12 weeks, twice a week, 45 minutes each time, for a total of 1080 minutes.
Study NCT06434493 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy
Description: All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy)
Study NCT06291090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OUD treatment intervention
Description: Participants received education on the diagnosis and management of OUD, have access to protocols to walk them through assessment of OUD using Diagnostic and Statistical Manual, fifth Edition (DSM)-5, COWS score to calculate severity of opioid withdrawal, buprenorphine or methadone initiation with pre-populated orders, and clickable links for OUD treatment referral post discharge.
Study NCT06535425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: The PG and JG were injected with autologous PRP at baseline. The injection was performed by the same clinician with 10 years of experience in knee joint injections. Participants were seated with their knees extended, and the needle was inserted through the joint space into the intra-articular cavity of the knee, administering approximately 2.5 mL of PRP into each knee joint. Thirty millilitres of venous blood were drawn from the participant's elbow vein, and approximately 5 mL of PRP was obtained for bilateral knee joint injection by using a TD5A tabletop low-speed centrifuge manufactured in China. The first centrifugation was performed at 2500 revolutions per minute (rpm) for 3 minutes, followed by a second centrifugation at 2300 rpm for 6 minutes.
Study NCT06535425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Contractions of Quadriceps
Description: The IG and JG exercises followed the methods of our previous research, with participants undergoing an 16-week ICQ intervention five times per week. Each session consisted of isometric contractions and relaxations of the quadriceps muscle for 5 seconds each, in sets of 30 repetitions, for a total of 10 sets, with a 30-second rest between sets. During this period, researchers conducted weekly follow-up calls or face-to-face interviews with participants to understand their living conditions, ensuring that they did not change their original lifestyle habits and did not engage in any other form of regular fitness activities. Participants who did not comply were not included in the final data analysis.
Study NCT06535425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps
Description: Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps
Study NCT06535425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Initially, all participants received identical health education in the form of thematic lectures once per week for 40 minutes each. The content included the following aspects: emphasising the importance of close cooperation with physicians as key to maintaining health; the process of the occurrence and development of KOA, along with its treatment methods; the role of family and social support in improving the condition; establishing a reasonable daily activity routine, such as protecting the affected knee joint, avoiding long-distance fatigue, mountain climbing, ascending and descending high-rise stairs and various adverse body postures (prolonged standing, kneeling and squatting); and advising those who are overweight to reduce their body weight. On this foundation, the four groups of participants underwent the following interventions.
Study NCT06535425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Initially, all participants received identical health education in the form of thematic lectures once per week for 40 minutes each. The content included the following aspects: emphasising the importance of close cooperation with physicians as key to maintaining health; the process of the occurrence and development of KOA, along with its treatment methods; the role of family and social support in improving the condition; establishing a reasonable daily activity routine, such as protecting the affected knee joint, avoiding long-distance fatigue, mountain climbing, ascending and descending high-rise stairs and various adverse body postures (prolonged standing, kneeling and squatting); and advising those who are overweight to reduce their body weight. On this foundation, the four groups of participants underwent the following interventions.
Study NCT06434493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent oral capecitabine chemotherapy
Description: All patients to be offered concurrent oral capecitabine 625mg/m2 twice daily on radiation days
Study NCT06434493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin & Gemcitabine intravenous chemotherapy
Description: Following chemoradiotherapy (PBT + capecitabine), and whilst on the liver transplant waiting list, patients will be offered up to 6 cycles of standard chemotherapy with cisplatin and gemcitabine.
Study NCT05822141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: For 12 weeks subjects will ingest 6 capsules per day of fish oil (7.8 g/day total omega--3 fatty acids: 3.75 g/day EPA and 1.5 g/day DHA)
Study NCT05822141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For 12 weeks subjects will ingest 6 capsules per day of olive oil (each capsule contains 990 mg of olive oil)
Study NCT04555044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinolipid
Description: Lipid injectable emulsion, USP 20%